Latest hypoglycemia Stories
ORLANDO, Fla., July 7, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and the advocacy organization Children with Diabetes, Inc.
DEERFIELD, Ill. and OSAKA, Japan, June 28, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that results from late breaking data presented by Takeda Global Research & Development Center, Inc.
SAN DIEGO, June 27, 2011 /PRNewswire/ -- Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.
SAN DIEGO, June 25, 2011 /PRNewswire/ -- Novo Nordisk will present data from two extension studies at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) which show that VictozaÂ® (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies.
PARIS, June 24, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data from a 60-week, open-label study that compared three intensified insulin regimens added to oral therapy for uncontrolled type 2 diabetes and found that using two regimens including LantusÂ® (insulin glargine [rDNA origin] injection) and ApidraÂ® (insulin glulisine [rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less hypoglycemia and improvement in...
PARIS, June 24, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data from four studies of its once-daily GLP-1 receptor agonist LyxumiaÂ® (lixisenatide) that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.
SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood sugar is not adequately controlled.
SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc.
SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc.
Guidance outlines recommendations for clinical trials and pathway to market approval SILVER SPRING, Md., June 20, 2011 /PRNewswire-USNewswire/ -- The U.S.
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
- A volcanic mudflow.